ProQR Therapeutics (NASDAQ:PRQR) Rating Increased to Buy at Citigroup

ProQR Therapeutics (NASDAQ:PRQR) was upgraded by stock analysts at Citigroup from a “neutral” rating to a “buy” rating in a research report issued on Monday,Briefing.com Automated Import reports. The firm currently has a $4.00 price objective on the biopharmaceutical company’s stock. Citigroup’s target price suggests a potential upside of 109.42% from the stock’s current price.

Several other research analysts also recently commented on PRQR. Oppenheimer started coverage on shares of ProQR Therapeutics in a report on Friday, January 10th. They issued an “outperform” rating and a $15.00 price target for the company. StockNews.com cut shares of ProQR Therapeutics from a “hold” rating to a “sell” rating in a report on Thursday, November 28th. Chardan Capital reissued a “buy” rating and set a $4.00 price objective on shares of ProQR Therapeutics in a research note on Thursday, December 12th. HC Wainwright restated a “buy” rating and issued a $10.00 target price on shares of ProQR Therapeutics in a research note on Thursday, December 12th. Finally, JMP Securities reaffirmed a “market outperform” rating and issued a $8.00 price target on shares of ProQR Therapeutics in a report on Thursday, December 12th. One analyst has rated the stock with a sell rating, five have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $9.17.

ProQR Therapeutics Stock Down 1.5 %

Shares of PRQR opened at $1.91 on Monday. ProQR Therapeutics has a twelve month low of $1.61 and a twelve month high of $4.62. The stock has a market cap of $156.01 million, a PE ratio of -5.97 and a beta of 0.24. The business’s 50-day moving average price is $2.34 and its 200-day moving average price is $2.63.

Institutional Investors Weigh In On ProQR Therapeutics

Several hedge funds have recently added to or reduced their stakes in the company. Alpine Global Management LLC bought a new position in ProQR Therapeutics during the fourth quarter valued at approximately $39,000. Woodline Partners LP purchased a new stake in ProQR Therapeutics in the 4th quarter worth approximately $9,426,000. Velan Capital Investment Management LP purchased a new stake in ProQR Therapeutics in the fourth quarter worth $107,000. Squarepoint Ops LLC boosted its stake in shares of ProQR Therapeutics by 16.3% during the 4th quarter. Squarepoint Ops LLC now owns 83,114 shares of the biopharmaceutical company’s stock valued at $220,000 after purchasing an additional 11,623 shares in the last quarter. Finally, Two Sigma Investments LP boosted its position in ProQR Therapeutics by 512.8% during the 4th quarter. Two Sigma Investments LP now owns 383,134 shares of the biopharmaceutical company’s stock valued at $1,015,000 after acquiring an additional 320,614 shares in the last quarter. Institutional investors own 32.65% of the company’s stock.

ProQR Therapeutics Company Profile

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1).